ClinicalTrials.gg
RecruitingNCT05876182VanC-ITUpdated Jul 25, 2025

Vancomycin in Primary Sclerosing Cholangitis in Italy

A Phase 2 interventional study of Oral Vancomycin and Placebo in Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder and IBD, sponsored by University of Milano Bicocca. Recruiting at 1 site in Italy. Open to participants aged 15 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by University of Milano Bicocca · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
15 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing vancomycin in Cholangitis, Sclerosing — 6 open to participants now, 6 under way, none of them phase 3. Vancomycin · Cholangitis, Sclerosing.

Planned enrollment
4th of 13
84 · median 32
Started
2023
the only one that year
Phase 2
3 of 13
3 open now
Registered
9th of 13
by date
Lead sponsor
1 of 13
University of Milano Bicocca

Among the 13 studies testing vancomycin in Cholangitis, Sclerosing, this one is the 4th largest by planned enrollment, is the only one that started in 2023, is one of 3 in phase 2, and was the 9th registered.

Cholangitis, Sclerosing

152 studies on the registry are indexed under Cholangitis, Sclerosing; 42 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

6 of the 13 studies testing vancomycin in Cholangitis, Sclerosing are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About vancomycin

Vancomycin: first FDA approval 1964 (VANCOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 15 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing vancomycin in Cholangitis, Sclerosing, or all of them as a file.
02

Study summary

Primary sclerosing cholangitis (PSC) is chronic fibroinflammatory disease of the liver. There is still no medical therapy proven to halt the progression of PSC or prevent its serious complications.

This is a Phase 2 randomized, double bind, placebo-controlled, monocentric study evaluating the safety and efficacy of two doses of oral vancomycin (i.e. 750 mg and 1500 mg/day) in subject between 15 - 70 years old with PSC.

Read the detailed description

Primary sclerosing cholangitis (PSC) is chronic fibroinflammatory disease of the liver characterized by chronic inflammation and sclerosis of the intrahepatic and/or extrahepatic bile ducts, and a risk for progression to liver failure and development of colorectal and hepatobiliary cancer. Both children and adults are affected. Patients with PSC have a diminished life expectancy with a median survival of 17 years after diagnosis. Despite the high mortality associated with PSC and the efforts to optimize its management, there is no medical therapy proven to halt the progression of PSC or prevent its serious complications. There is a strong yet poorly understood relationship between PSC and inflammatory bowel disease (IBD); nearly 70%-80% of PSC patients have IBD, mainly ulcerative colitis (UC). Increasing evidence is pointing out the role of gut microbiota in the pathogenesis of PSC. The 'leaky gut' theory implies that either bacteria or their toxic metabolites translocate from the inflamed intestinal mucosa into the portal circulation and into the liver causing liver and biliary injury. The gut microbiota of PSC patients, compared to IBD patients and healthy controls, showed decreased microbial diversity, and over-represented intestinal pathobionts (i.e., organisms which, under normal circumstances, lives as a non-harming symbiont). Several antibiotics, including vancomycin and metronidazole, have been investigated in PSC. The use of oral vancomycin (OV), a glycopeptide antibiotic has been reported to be associated with improvement in clinical symptoms and laboratory abnormalities in patients with PSC; however, prospective studies in adult and young adult patients in Europe are lacking.

Our scientific community therefore seeks to examine the safety and efficacy of OV in patients with PSC in a randomized placebo-controlled clinical trial.

This is a Phase 2 randomized, double bind, placebo-controlled, monocentric study evaluating the safety and efficacy of two doses of oral vancomycin (i.e. 750 mg and 1500 mg/day) in subject between 15 - 70 years old with PSC with or without IBD. The study will consist of 10-week screening period (including a run-in phase), 24 weeks of treatment, and follow-up visits at 4 and 12 weeks after completion of treatment to evaluate what happens after treatment stop. Subjects will be randomized to placebo or treatment and stratifying by baseline presence of fibrosis by fibroscan value at baseline (\< or ≥14.4 kPa corresponding to F4 fibrosis), as this parameter could affect the likelihood of reaching the primary composite outcome measure.

The knowledge gained from our proposed clinical trial will help us determine if OV should be considered as a treatment option in patients with PSC. Furthermore, the use of state-of-the art technology applied in this study will shed light on the relationship between the gut microbiome, bile acids, immune-mediators, including cytokines, and PSC.

03

Conditions studied

  • Primary Sclerosing Cholangitis
  • Liver and Intrahepatic Bile Duct Disorder
  • IBD

Keywords

  • liver
  • oral vancomycin
  • primary sclerosing cholangitis
  • Inflammatory bowel disease
04

Who can participate

Ages eligible
15 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give prior to any study specific procedure being performed;
  2. Male and non-pregnant, non-lactating female subjects, including women of child bearing potential (), between 15-70 years of age at the time of informed consent;
  3. Diagnosis of large-duct PSC based on cholangiogram (at MRCP, ERCP, PTC) according to the most recent published guidelines (EASL);
  4. Baseline ALP ≥1.5 times upper limit normal at screening;
  5. Absence of biliary obstruction and/or within 6-12 months of entry into the study;
  6. If a patient is on ursodeoxycholic acid (UDCA) or 5-aminosalicylic acid he or she is expected to remain on the same daily dose during the study period;
  7. Patients who received antibiotics or probiotics may participate if they had a of at least 3-month prior to study entry;
  8. If a patient has been on obeticholic acid or other experimental therapies (e.g. cilofexor and norUDCA) for PSC, they must complete a 3-month washout period before study entry;
  9. PSC with or without IBD. IBD diagnosis should be documented and with a minimum disease duration of 6 months, as determined by endoscopic and histopathology assessment. IBD should be in clinical remission or mildly active according to CDAI and partial Mayo score for CD and UC, respectively (i.e. patients with CDAI score \< 220 and pMayo score \<5). Patients without documented IBD need a colonoscopy with segmental within 12 months prior to baseline visit;
  10. Female subjects of childbearing potential must test negative for pregnancy at screening, baseline and follow-up visits and if engage in sexual intercourse must agree to use specific methods of .
  11. Male subjects with female partners of childbearing potential must use condoms during treatment and until the end of relevant systemic exposure.

Exclusion criteria

Exclusion Criteria:

  1. Receiving an antibiotic or probiotic within 3 months prior to the study;
  2. Expected to receive antibiotics within the weeks leading up to enrollment (such as patients with recurrent cholangitis, ongoing infectious illnesses, etc.);
  3. Allergy to vancomycin or teicoplanin;
  4. Biliary intervention within 3 months prior to study enrollment or planned;
  5. Alcohol abuse (defined as greater than 14 standard drinks units per week in men; greater than 7 standard drinks units per week);
  6. Pregnancy and lactation;
  7. Advanced renal disease (\< 70);
  8. Active and/or C infection;
  9. Other chronic or cholestatic liver diseases such as PBC, hepatitis, nonalcoholic steatohepatitis, alcoholic liver disease, Wilson's disease, hemochromatosis, α-1 antitrypsin deficiency, IgG4-related sclerosing cholangitis, and liver cancer;
  10. History of CCA;
  11. Advanced liver disease (history of variceal bleeding, ascites, hepatic encephalopathy, and/or bilirubine >4 mg/dL);
  12. On active transplantation list;
  13. IBD with uncontrolled moderate to severe activity;
  14. Active treatment or within the previous four weeks () with any medication for controlling IBD (i.e. azathioprine, 6-mercaptopurine, tacrolimus, methotrexate, infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, ozanimod). Treatment with (including budesonide, budesonide MMX and beclomethasone) in the previous four weeks
  15. Active treatment with rifampicin or within the previous three months (washout period);
  16. Dose change within last 3 months prior to baseline of concomitant treatment with vitamin D or fibrates;
  17. Treatment with any experimental drug within the previous three months;
  18. Any known relevant infectious disease (e.g. active tuberculosis, AIDS defining disease);
  19. History or active hearing problems;
  20. Any active malignant disease;
  21. Well found doubt about patient's cooperation, e.g. addiction to alcohol or drugs;
  22. Imprisoned person, person admitted to nursing homes, persons under legal guardianship, and persons not able to express their consent.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Oral Vancomycin 750

    28 subjects with PSC will be randomized to this arm. They will take 2 tablet (1 of vancomycin 250 mg and 1 of placebo), three times a day administered orally (total dose 750 mg/daily).

    Drug: Oral Vancomycin

  • Experimental
    Oral Vancomycin 1500

    28 subjects with PSC will be randomized to this arm.They will take 2 tablet of 250 mg of vancomycin three times a day administered orally (total dose 1500mg/daily)

    Drug: Oral Vancomycin

  • Placebo comparator
    Placebo

    28 subjects with PSC will be randomized to this arm. They will take 2 tablet (placebo-to-match oral vancomycin) administered orally three times a day.

    Other: Placebo

Interventions

  • DrugVancomycinStudies of VancomycinVancomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.

    Also known as: OV

  • OtherPlacebo

    The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.

06

What researchers measure

Primary outcomes

  1. Change from baseline in alkaline phosphatase (ALP) levels

    ALP levels at 6 months

    Time frame: From baseline to 6 months

Secondary outcomes

  1. Safety and tolerability of OV in each treatment arm

    Adverse events

    Time frame: From baseline to 6 months

  2. Clinical hematology

    White blood cells (10\^3/uL)

    Time frame: From baseline to 6 months

  3. Clinical hematology

    Hemoglobin (g/dl)

    Time frame: From baseline to 6 months

  4. Clinical hematology

    Hematocrit (%)

    Time frame: From baseline to 6 months

  5. Clinical hematology

    MCV (Mean Corpuscular Volume) (fL)

    Time frame: From baseline to 6 months

  6. Clinical hematology

    Platelets (10\^3/uL)

    Time frame: From baseline to 6 months

  7. Clinical hematology

    Absolute neutrophils (10\^3/uL)

    Time frame: From baseline to 6 months

  8. Clinical hematology

    Absolute lymphocytes (10\^3/uL)

    Time frame: From baseline to 6 months

  9. Clinical hematology

    PT (Prothrombin Time, Ratio)

    Time frame: From baseline to 6 months

  10. Clinical hematology

    INR

    Time frame: From baseline to 6 months

  11. Clinical chemistry

    Total proteins (g/dl)

    Time frame: From baseline to 6 months

  12. Clinical chemistry

    Albumin (g/dl)

    Time frame: From baseline to 6 months

  13. Clinical chemistry

    Gamma (g/dl)

    Time frame: From baseline to 6 months

  14. Clinical chemistry

    Sodium (mmol/l)

    Time frame: From baseline to 6 months

  15. Clinical chemistry

    Creatinine (mg/dl)

    Time frame: From baseline to 6 months

  16. Clinical chemistry

    Potassium (mmol/l)

    Time frame: From baseline to 6 months

  17. Clinical chemistry

    Urea (mg/dl)

    Time frame: From baseline to 6 months

  18. Clinical chemistry

    Glucose (mg/dl)

    Time frame: From baseline to 6 months

  19. Clinical chemistry

    Total bilirubin (mg/dl)

    Time frame: From baseline to 6 months

  20. Clinical chemistry

    Direct bilirubin (mg/dl)

    Time frame: From baseline to 6 months

  21. Clinical chemistry

    GGT (U/l)

    Time frame: From baseline to 6 months

  22. Clinical chemistry

    AST (U/l)

    Time frame: From baseline to 6 months

  23. Clinical chemistry

    ALT (U/l)

    Time frame: From baseline to 6 months

  24. Clinical chemistry

    Triglycerides (mg/dl)

    Time frame: From baseline to 6 months

  25. Clinical chemistry

    Cholesterol (Total) (mg/dl)

    Time frame: From baseline to 6 months

  26. Clinical chemistry

    High Density Lipoprotein (HDL Cholesterol) (mg/dl)

    Time frame: From baseline to 6 months

  27. Clinical chemistry

    PCR (C Reactive Protein) (mg/dl)

    Time frame: From baseline to 6 months

  28. Clinical chemistry

    IgG (mg/dl)

    Time frame: From baseline to 6 months

  29. Clinical chemistry

    IgA (mg/dl)

    Time frame: From baseline to 6 months

  30. Clinical chemistry

    IgM (mg/dl)

    Time frame: From baseline to 6 months

  31. Clinical chemistry

    Ferritin (ng/ml)

    Time frame: From baseline to 6 months

  32. Single 12-lead electrocardiograms

    Sinus rhythm

    Time frame: From baseline to 6 months

  33. Single 12-lead electrocardiograms

    QTc (msec)

    Time frame: From baseline to 6 months

  34. Urine analysis

    pH

    Time frame: From baseline to 6 months

  35. Urine analysis

    Specific gravity

    Time frame: From baseline to 6 months

  36. Urine analysis

    Hemoglobin

    Time frame: From baseline to 6 months

  37. Urine analysis

    ACR (mg/g)

    Time frame: From baseline to 6 months

  38. Urine analysis

    PCR (mg/g)

    Time frame: From baseline to 6 months

  39. Vital sign measurements

    Body weight (kg)

    Time frame: From baseline to 6 months

  40. Vital sign measurements

    Systolic blood pressure (mmHg)

    Time frame: From baseline to 6 months

  41. Vital sign measurements

    Diastolic blood pressure (mmHg)

    Time frame: From baseline to 6 months

  42. Vital sign measurements

    Heart Rate (bpm)

    Time frame: From baseline to 6 months

  43. Vital sign measurements

    Temperature (°C)

    Time frame: From baseline to 6 months

  44. Changes in the PSC score

    Revised Mayo Risk Score (Calculation formula = 0.03 (age \[y\]) + 0.54 loge (bilirubin \[mg/dL\]) + 0.54 loge (aspartate aminotransferase \[U/L\]) + 1.24 (variceal bleeding \[0/1\]) - 0.84 (albumin \[g/dL\]) (Higher scores indicate greater disease severity)

    Time frame: From baseline to 6 months

  45. Changes in the IBD score

    Clinical Mayo Score (Partial Mayo Score) -(0-1=Remission; 2-4 = Mild activity; 5-7 = Moderate activity; 7-9 = Severe activity)

    Time frame: From baseline to 6 months

  46. Liver stiffness measurements

    Stiffness (kPa/s)

    Time frame: From baseline to 6 months

  47. Liver stiffness measurements

    Stiffness IQR/median (%)

    Time frame: From baseline to 6 months

  48. Liver stiffness measurements

    CAP (dB/m)

    Time frame: From baseline to 6 months

  49. Liver stiffness measurements

    CAP IQR/median (%)

    Time frame: From baseline to 6 months

  50. MRCP (Magnetic Resonance Cholangiopancreatography)

    Disease localisation

    Time frame: From baseline to 6 months

  51. MRCP (Magnetic Resonance Cholangiopancreatography)

    Presence of dominant stenosis

    Time frame: From baseline to 6 months

  52. MRCP (Magnetic Resonance Cholangiopancreatography)

    Radiological signs of cirrhosis

    Time frame: From baseline to 6 months

  53. Cytokines changes

    TGF-β levels

    Time frame: From baseline to 6 months

  54. Cytokines changes

    IL-4 levels

    Time frame: From baseline to 6 months

  55. Cytokines changes

    IL-13 levels

    Time frame: From baseline to 6 months

  56. Cytokines changes

    IL-10 levels

    Time frame: From baseline to 6 months

  57. Changes in the peripheral blood mononuclear cells

    Th1 and Th17 subsets isolation and analyses

    Time frame: From baseline to 6 months

  58. Patients quality of life

    Visual analogue scale (VAS) score for itch

    Time frame: From baseline to 6 months

  59. Patients quality of life

    Chronic Liver Disease Questionnaire (CLDQ)

    Time frame: From baseline to 6 months

  60. Patients quality of life

    EQ-5D-5L questionnaire

    Time frame: From baseline to 6 months

  61. Patients quality of life

    PSC patient reported outcome (PSC-PRO) questionnaire

    Time frame: From baseline to 6 months

  62. Patients quality of life

    Inflammatory Bowel Disease Questionnaire (IBDQ)

    Time frame: From baseline to 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cristoferi L, D'Amato D, Maino C, Bernasconi D, Dinelli ME, Malandrin SMI, Facciotti F, Vigano C, Pirola L, Festa MM, Gerussi A, Rossi E, Malinverno F, Tettamanti P, Cazzaniga ME, Corso R, Ippolito D, Galimberti S, Invernizzi P, Carbone M. Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial. BMJ Open. 2026 Jan 9;16(1):e106630. doi: 10.1136/bmjopen-2025-106630. PubMed 41513411 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2026, 36 months after the start.

Of 23 phase 2 interventional studies under Cholangitis, Sclerosing, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 62. This study's planned 36 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2023
First posted
May 25, 2023
StartActual
Jun 15, 2023
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05876182
Collaborators
Genetic s.p.a.
Responsible party
Sponsor
First posted
May 25, 2023
Start date
Jun 15, 2023
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jul 25, 2025

Study contacts

Marco Carbone, MD
Contact
marco.carbone@unimib.it
0392334515
Pietro Invernizzi, MD
Contact
pietro.invernizzi@unimib.it
039 233 2187

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vancomycin

Start the discussion